| Literature DB >> 26779417 |
Antonio Pierini1, Dominik Schneidawind2, Hidekazu Nishikii3, Robert S Negrin4.
Abstract
Broad clinical interest rapidly followed the recent discovery of different subpopulations of T cells that have immune regulatory properties and a number of studies have been conducted aiming to dissect the translational potential of these promising cells. In this review we will focus on forkhead box P3 (FoxP3) positive regulatory T cells, T regulatory type 1 cells and invariant natural killer T cells (iNKT). We will analyze their ability to correct immune dysregulation in animal models of immune mediated diseases and we will examine the first clinical approaches where these cells have been directly or indirectly employed. We will discuss successes, challenges and limitations that rose in the road to the clinical use of regulatory T cells.Entities:
Keywords: FoxP3+ T regulatory cells; Graft versus Host Disease; Hematopoietic Stem Cell Transplantation; Invariant Natural Killer T cells; T regulatory type 1 cells; Tolerance Induction
Year: 2015 PMID: 26779417 PMCID: PMC4712720 DOI: 10.1007/s40778-015-0025-1
Source DB: PubMed Journal: Curr Stem Cell Rep